Hypomethylating agents as emerging therapeutics for triple-negative breast cancer
Life Sciences · 2025
DOI: 10.1016/j.lfs.2025.123403 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Life Sciences, 2025. Verfasst von Nik Mohd Asri Nik Amirah Auni und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, DNA Methylation, Antimetabolites, Antineoplastic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 121 Literaturangaben. Gefördert von: Malaysia Ministry of Higher Education.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) is recognized as the most aggressive subtype of breast cancer. Epigenetic silencing, such as DNA methylation mediated by DNA methyltransferases (DNMTs) plays key roles in TNBC tumorigenesis. Hypomethylating agents (HMAs) such as azacitidine, decitabine, and guadecitabine are key inhibitors of DNMTs, and accumulating evidence has shown their immunogenicity properties. In this review, the efficacy and anti-tumor immune responses triggered by HMAs in TNBC are presented and discussed. Essentially, overexpression of DNMTs is associated with poor prognosis and reduced TNBC survival rates, and these effects are negated by HMAs. In particular, HMAs could reverse epigenetic silencing of tumor suppressor genes and enhance immune recognition of TNBC cells. Clinical trials of HMAs in TNBCs are limited but early-stage trials indicate that HMAs are safe and tolerable. More clinical studies are required to establish the effectiveness of HMAs against the disease, as supported by preclinical data substantiating their effectiveness especially guadecitabine. Future research should focus on optimizing dosing and exploring combinations with immunotherapies to maximize the potential of HMAs in TNBC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia.
- Department of Chemical Pathology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia.
- Department of Surgery, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia.
- Department of Immunology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia. Electronic address: kahkeng@usm.my.
Förderung
- Malaysia Ministry of Higher Education
Zitieren
APA
Nik Amirah Auni, N. M. A., Mohd Redzwan, N., Fauzi, A. N., Yahya, M. M., & Wong, K. K. (2025). Hypomethylating agents as emerging therapeutics for triple-negative breast cancer. Life Sciences. https://doi.org/10.1016/j.lfs.2025.123403
Vancouver
Nik Amirah Auni NMA, Mohd Redzwan N, Fauzi AN, Yahya MM, Wong KK. Hypomethylating agents as emerging therapeutics for triple-negative breast cancer. Life Sciences. 2025. doi:10.1016/j.lfs.2025.123403
BibTeX
@article{NikAmirahAuni2025,
author = {Nik Amirah Auni, Nik Mohd Asri and Mohd Redzwan, Norhanani and Fauzi, Agustine Nengsih and Yahya, Maya Mazuwin and Wong, Kah Keng},
title = {Hypomethylating agents as emerging therapeutics for triple-negative breast cancer},
journal = {Life Sciences},
year = {2025},
doi = {10.1016/j.lfs.2025.123403}
}
EUVIMED